Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia ; volume:12 ; number:1 ; day:28 ; month:6 ; year:2019 ; pages:1-14 ; date:12.2019
Journal of hematology & oncology ; 12, Heft 1 (28.6.2019), 1-14, 12.2019
- Creator
-
Brzezinka, Krzysztof
Nevedomskaya, Ekaterina
Lesche, Ralf
Steckel, Michael
Eheim, Ashley L.
Haegebarth, Andrea
Stresemann, Carlo
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-019-0749-y
- URN
-
urn:nbn:de:101:1-2019102313422569342731
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Brzezinka, Krzysztof
- Nevedomskaya, Ekaterina
- Lesche, Ralf
- Steckel, Michael
- Eheim, Ashley L.
- Haegebarth, Andrea
- Stresemann, Carlo
- SpringerLink (Online service)
Other Objects (12)
RNA binding proteins in MLL-rearranged leukemia
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Using genome editing to model MLL rearranged leukemias
MLL-r Leukemia
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia
Molecular pathogenesis of disease progression in MLL-rearranged AML
Identification of potential targets for palbociclib combination therapy in the context of MLL-rearranged acute myeloid leukemia
A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
Transient spontaneous remission in congenital MLL-AF10 rearranged acute myeloid leukemia presenting with cardiorespiratory failure and meconium ileus
RNA binding proteins in MLL-rearranged leukemia
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Using genome editing to model MLL rearranged leukemias
MLL-r Leukemia
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia
Molecular pathogenesis of disease progression in MLL-rearranged AML
Identification of potential targets for palbociclib combination therapy in the context of MLL-rearranged acute myeloid leukemia
A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
Transient spontaneous remission in congenital MLL-AF10 rearranged acute myeloid leukemia presenting with cardiorespiratory failure and meconium ileus
RNA binding proteins in MLL-rearranged leukemia
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Using genome editing to model MLL rearranged leukemias
MLL-r Leukemia
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia
Molecular pathogenesis of disease progression in MLL-rearranged AML
Identification of potential targets for palbociclib combination therapy in the context of MLL-rearranged acute myeloid leukemia
A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair